Estrogen Receptor Expression in Pancreatic Adenocarcinoma: Time to Reconsider Evidence.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
15
3
2022
Statut:
ppublish
Résumé
Pancreatic adenocarcinoma remains a chemotherapy-resistant and refractory malignancy with high mortality, unaffected by recent progress in anticancer treatment. Expression of estrogen receptors was detected almost 50 years ago, in both benign and malignant pancreatic cells. However, early preclinical studies in pancreatic cancer led to contradictory findings, and most clinical studies failed to demonstrate an effect with tamoxifen treatment. The identification of a second form of estrogen receptor seems to provide some explanation for these discrepancies. Predominantly expressed in malignant cells and structurally different from what was considered the only estrogen receptor, estrogen receptor β was recognized as a negative prognostic factor and a possible therapeutic target in pancreatic ductal adenocarcinoma. Therefore, findings of research before the identification of estrogen receptor β should be reconsidered, and further studies should be designed to reassess the expression and effect of this specific estrogen receptor type in pancreatic cancer.
Identifiants
pubmed: 34860807
doi: 10.1097/MPA.0000000000001921
pii: 00006676-202110000-00002
doi:
Substances chimiques
Estrogen Receptor alpha
0
Estrogen Receptor beta
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1250-1253Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Carioli G, Bertuccio P, Boffetta P, et al. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol . 2020;31:650–658.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin . 2020;70:7–30.
Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science . 2008;321:1801–1806.
Maitra A. Pancreatic cancer hidden in plain sight. Nature . 2020;581:34–35.
Sandberg AA, Kirdani RY, Varkarakis MJ, et al. Estrogen receptor protein of pancreas. Steroids . 1973;22:259–271.
Tiano J, Mauvais-Jarvis F. Selective estrogen receptor modulation in pancreatic β-cells and the prevention of type 2 diabetes. Islets . 2012;4:173–176.
Greenway B, Iqbal MJ, Johnson PJ, et al. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J (Clin Res Ed) . 1981;283:751–753.
Fernandez E, La Vecchia C, D'Avanzo B, et al. Menstrual and reproductive factors and pancreatic cancer risk in women. Int J Cancer . 1995;62:11–14.
Fukushima N, Fukayama M. Mucinous cystic neoplasms of the pancreas: pathology and molecular genetics. J Hepatobiliary Pancreat Surg . 2007;14:238–242.
Theve NO, Pousette A, Carlström K. Adenocarcinoma of the pancreas—a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol . 1983;9:193–197.
Pettersen A, Lea O, Bakkevold K, et al. Progress in pancreatic oestrogen receptors. Eur J Surg Oncol . 1986;12:321–324.
Andrén-Sandberg A, Johansson J. Influence of sex hormones on pancreatic cancer. Int J Pancreatol . 1990;7:167–176.
Bakkevold KE, Pettersen A, Arnesjø B, et al. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg . 1990;77:725–730.
Taylor OM, Benson EA, McMahon MJ. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumour Group. Br J Surg . 1993;80:384–386.
Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett . 1996;392:49–53.
Barkhem T, Carlsson B, Nilsson Y, et al. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol . 1998;54:105–112.
Seeliger H, Pozios I, Assmann G, et al. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma. BMC Cancer . 2018;18:1049.
Younes M, Ly CJ, Singh K, et al. Expression of estrogen receptor beta isoforms in pancreatic adenocarcinoma. Oncotarget . 2018;9:37715–37720.
Rosenthal HE, Sandberg AA. Estrogen binding proteins in rat pancreas. J Steroid Biochem . 1978;9:1133–1139.
Sandberg AA, Rosenthal HE. Steroid receptors in exocrine glands: the pancreas and prostate. J Steroid Biochem . 1979;11:293–299.
Molteni A, Bahu RM, Battifora HA, et al. Estradiol receptor assays in normal and neoplastic tissues. A possible diagnostic acid for tumor differentiation. Ann Clin Lab Sci . 1979;9:103–108.
Pousette A, Carlström K, Sköldefors H, et al. Purification and partial characterization of a 17 beta-estradiol-binding macromolecule in the human pancreas. Cancer Res . 1982;42:633–637.
Grossman A, Richardson SB, Altszuler N, et al. Evidence that the [3H]estradiol-binding protein in pancreas is localized in exocrine cells. Endocrinology . 1985;116:2221–2226.
Pousette A, Fernstad R, Theve NO, et al. Further characterization of the estrogen binding macromolecule in human pancreas. J Steroid Biochem . 1985;23:115–119.
Andrén-Sandberg A. Estrogens and pancreatic cancer: some recent aspects. Scand J Gastroenterol . 1986;21:129–133.
Pousette A, Fernstad R, Sköldefors H, et al. Analysis of an estrogen binding macromolecule in human pancreas by radioimmunoassay. J Steroid Biochem . 1987;26:439–442.
Bourhis J, Lacaine F, Augusti M, et al. Protective effect of oestrogen in pancreatic cancer. Lancet . 1987;2:977.
Devesa SS, Silverman DT. Protective effect of oestrogen in pancreatic cancer. Lancet . 1988;2:905–906.
Lhoste EF, Roebuck BD, Brinck-Johnsen T, et al. Effect of castration and hormone replacement on azaserine-induced pancreatic carcinogenesis in male and female Fischer rats. Carcinogenesis . 1987;8:699–703.
Sumi C, Longnecker DS, Roebuck BD, et al. Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine. Cancer Res . 1989;49:2332–2336.
Longnecker DS, Sumi C. Effects of sex steroid hormones on pancreatic cancer in the rat. Int J Pancreatol . 1990;7:159–165.
Benz C, Hollander C, Miller B. Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res . 1986;46:2276–2281.
Targarona EM, Pons MD, Gonzalez G, et al. Is exocrine pancreatic cancer a hormone-dependent tumor? A study of the existence of sex hormone receptors in normal and neoplastic pancreas. Hepatogastroenterology . 1991;38:165–169.
Taylor OM, Teasdale J, Cowen PN, et al. Classical oestrogen receptor is not detectable in pancreatic adenocarcinoma. Br J Cancer . 1992;66:503–506.
Mao C, Desaty D, Howard JM. Cytosolic estrogen and progesterone receptors in exocrine pancreatic adenocarcinoma. Int J Pancreatol . 1994;15:155–156.
Ollayos CW, Riordan GP, Rushin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med . 1994;118:630–632.
Tønnesen K, Kamp-Jensen M. Antiestrogen therapy in pancreatic carcinoma: a preliminary report. Eur J Surg Oncol . 1986;12:69–70.
Wong A, Chan A, Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep . 1987;71:749–750.
Crowson MC, Dorrell A, Rolfe EB, et al. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur J Surg Oncol . 1986;12:335–336.
Kuramoto M, Yamashita J, Ogawa M. Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells. Cancer . 1995;75:1263–1272.
Singh S, Baker PR, Poulsom R, et al. Expression of oestrogen receptor and oestrogen-inducible genes in pancreatic cancer. Br J Surg . 1997;84:1085–1089.
Pozios I, Knösel T, Zhao Y, et al. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol . 2018;144:1887–1897.
Kondoh K, Tsuji N, Asanuma K, et al. Inhibition of estrogen receptor beta-mediated human telomerase reverse transcriptase gene transcription via the suppression of mitogen-activated protein kinase signaling plays an important role in 15-deoxy-Delta(12,14)-prostaglandin J(2)-induced apoptosis in cancer cells. Exp Cell Res . 2007;313:3486–3496.
Iwao K, Miyoshi Y, Ooka M, et al. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in human pancreatic cancers by real-time polymerase chain reaction. Cancer Lett . 2001;170:91–97.
Konduri S, Schwarz RE. Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens. J Surg Res . 2007;140:55–66.
Martín-Santamaría S, Rodríguez JJ, de Pascual-Teresa S, et al. New scaffolds for the design of selective estrogen receptor modulators. Org Biomol Chem . 2008;6:3486–3496.